Hiroki Yoshihara

Recommendations for generating real-world evidence with regulatory-grade relevance and reliability.

Real-world data (RWD) and real-world evidence (RWE) are increasingly incorporated into regulatory decision-making to complement randomized controlled trials (RCTs), particularly in settings where conventional trial designs are infeasible, such as rare diseases, rare molecular subtypes, and post-marketing evaluation. Ac...